

PAION AG

Germany / Biotechnology
 Frankfurt Prime Standard
 Bloomberg: PA8 GR
 ISIN: DE000A0B65S3

Update

RATING

PRICE TARGET

Return Potential
 Risk Rating

BUY

€ 3.80

173.8%
 High

LOW VALUATION RELATIVE TO POTENTIAL

Last year PAION's partners launched remimazolam in the US for procedural sedation and in South Korea for general anaesthesia while PAION has itself launched the product for procedural sedation in the UK (August 2021), the Netherlands (September 2021) and Denmark (September 2021). These launches followed market introductions by partners for general anaesthesia in Japan and for procedural sedation in China in 2020. In early 2021, PAION announced the acquisition of exclusive European commercialisation rights for the vasoconstrictor, angiotensin II, and the tetracycline-class antibiotic, eravacycline. Both drugs are approved in the US and Europe. PAION has so far launched angiotensin II in Germany (July 2021) and eravacycline in the Netherlands (September 2021). The company plans to continue the staggered launch of all three products on key European markets over the next two years. Remimazolam was listed at 400 hospitals in Japan at the end of 2020 and in the US the drug is expected to have been on formulary at the targeted number of 150 accounts by the end of last year. Despite this, we model royalty income from partners of only €1.2m for 2021. In Japan business was affected by a contamination-related batch recall and in the US by the pandemic-related postponement of elective surgical procedures and difficulty in accessing clinics and prescribing doctors. Meanwhile, in the EU/UK we pencil in revenue of only €0.2m for 2021. Supplies of active pharmaceutical ingredient (API) and milestone payments make up the balance of our 2021 revenue forecast of €7.1m. Nevertheless, we remain confident of PAION's long term success and expect traction to improve substantially as the EU marketing effort is strengthened and the pandemic eases. We continue to find PAION's 2026 target for revenue and EBITDA of €200m and €100m respectively, realistic. We maintain our Buy recommendation but lower the price target from €4.10 to €3.80. The reduction mainly reflects lower near term profitability than forecast in our most recent note of July 2021 as well as the removal of the ICU indication from our model. (p.t.o.)

FINANCIAL HISTORY & PROJECTIONS

	2020	2021E	2022E	2023E	2024E	2025E
Revenue (€m)	19.66	7.05	39.55	37.53	93.23	213.76
Y-o-y growth	145.7%	-64.1%	460.8%	-5.1%	148.4%	129.3%
EBIT (€m)	1.58	-20.25	1.64	-13.83	7.55	58.84
EBIT margin	8.1%	-287.1%	4.2%	-36.8%	8.1%	27.5%
Net income (€m)	2.22	-23.08	-0.06	-17.93	3.45	55.43
EPS (diluted) (€)	0.03	-0.33	0.00	-0.25	0.04	0.58
DPS (€)	0.00	0.00	0.00	0.00	0.00	0.00
FCF (€m)	0.89	-39.79	0.55	-19.23	-2.86	40.00
Net gearing	-88.6%	231.6%	199.4%	-289.1%	-453.6%	-9.7%
Liquid assets (€m)	19.67	9.06	9.75	20.52	10.85	39.94

RISKS

Risks to our price target include but are not limited to: acceptance of the company's products, financial, and regulatory risks.

COMPANY PROFILE

PAION is a specialty pharmaceutical company headquartered in Aachen (Germany). PAION's lead substance, remimazolam, is an intravenous ultra-short-acting benzodiazepine anaesthetic with multiple approvals in different regions and in different indications. The company is currently also launching the vasoconstrictor, angiotensin II, and the tetracycline-class antibiotic, eravacycline, in the EU and the UK.

MARKET DATA

As of 28 Jan 2022

Closing Price	€ 1.39
Shares outstanding	71.30m
Market Capitalisation	€ 98.96m
52-week Range	€ 1.20 / 2.49
Avg. Volume (12 Months)	115,345

Multiples	2020	2021E	2022E
P/E	41.1	n.a.	n.a.
EV/Sales	5.5	15.2	2.7
EV/EBIT	67.7	n.a.	65.3
Div. Yield	0.0%	0.0%	0.0%

STOCK OVERVIEW



COMPANY DATA

As of 30 Sep 2021

Liquid Assets	€ 13.14m
Current Assets	€ 20.90m
Intangible Assets	€ 19.78m
Total Assets	€ 43.15m
Current Liabilities	€ 9.74m
Shareholders' Equity	€ 12.13m

SHAREHOLDERS

Cosmo Pharmaceuticals	8.2%
Free Float	91.8%



Figure 1: Changes to our forecasts

in €m	2021E			2022E			2023E	2024E	2025E	2026E
	Old	New	Δ	Old	New	Δ	New	New	New	New
Product revenues	6.53	4.45	-31.8%	28.30	10.55	-62.7%	32.20	90.08	212.28	397.16
of which:										
EU+UK product revenues	0.37	0.18	-50.4%	11.33	2.57	-77.3%	12.49	45.40	117.15	209.84
Partner royalties	1.81	1.16	-36.0%	4.92	2.56	-48.0%	6.46	14.69	31.55	63.30
API	4.35	3.11	-28.5%	12.05	5.42	-55.0%	13.25	29.99	63.57	124.02
Other operating income	2.50	2.60	4.0%	2.00	29.00	1350.0%	5.33	3.15	1.48	9.00
Total revenues	9.03	7.05	-21.9%	30.30	39.55	30.5%	37.53	93.23	213.76	406.16
Cost of goods sold	3.99	3.18	25.3%	16.58	6.41	158.8%	16.87	42.51	94.85	176.52
% revenues	61.1%	71.5%	-	58.6%	60.7%	-	52.4%	47.2%	44.7%	44.4%
Gross profit	5.04	3.87	-23.3%	13.72	33.14	141.6%	20.67	50.72	118.91	229.65
% revenues	55.8%	54.8%	-	45.3%	83.8%	-	55.1%	54.4%	55.6%	56.5%
SG&A	19.00	19.00	0.0%	33.33	26.50	25.8%	29.49	38.17	55.06	62.95
% revenues	291.0%	426.7%	-	117.8%	251.2%	-	91.6%	42.4%	25.9%	15.9%
R&D	5.00	5.00	0.0%	5.00	5.00	0.0%	5.00	5.00	5.00	2.00
% revenues	55.4%	112.3%	-	17.7%	47.4%	-	15.5%	5.6%	2.4%	0.5%
EBIT	-18.96	-20.25	n.a.	-24.62	1.64	n.a.	-13.83	7.55	58.84	164.69
% total revenues	-210.0%	-287.1%	-	-5.0%	4.2%	-	-36.8%	8.1%	27.5%	40.5%
Net income	-20.07	-23.08	n.a.	-26.12	-0.06	n.a.	-17.93	3.45	55.43	162.37
% total revenues	-222.3%	-327.2%	-	-86.2%	-0.1%	-	-47.8%	3.7%	25.9%	40.0%
EPS (dil., in EUR)	-0.29	-0.33	n.a.	-0.34	0.00	n.a.	-0.25	0.04	0.58	1.71
EBITDA	-17.37	-18.31	n.a.	-23.03	3.58	n.a.	-11.89	9.49	60.78	166.63

Source: First Berlin Equity Research forecasts

2022 other op. income forecast includes €20.5m from sale of Chinese royalties

Changes to our forecasts in figure 1 reflect a slower increase in product revenues than we modelled in our most recent note of July 2021. The reduction in our projections is attributable to the resurgence of the COVID-19 pandemic in the form of the omicron variant and also our previous expectation that PAION would be able to build up an own sales force in the EU more quickly than has proved to be the case. Our near term partner royalty forecast is also impacted by the sale of future remimazolam royalties to Chinese partner Humanwell for €20.5m announced on 7 January. This figure was close to our €21.7m July 2021 valuation of the Chinese royalty stream. The inclusion of the €20.5m sales proceeds in 2022 other operating income is the biggest contributor to the increase in our forecast for this number. But PAION has also announced its near term intention to license out remimazolam in non-core EU markets and additional markets outside the EU, and we project an additional €5m in 2022 other operating income as a result of these efforts. Lastly, PAION stated in the H1/21 report published in August that further development of remimazolam for the ICU is currently not being conducted. Our forecasts from 2024 therefore no longer include any contribution from this source.

Our reworked 2021 forecasts are close to PAION's current guidance (see figure 2) first given in August 2021 at the time of the H1 results. The difference between our forecast and guidance is that we project other operating income (milestone/upfront payments) of €2.6m instead of €4-5m, as licensing deals originally projected by PAION for 2021 are now expected this year.


Figure 2: Most recent PAION 2021 guidance (August 2021)

	Guidance FY2021	Comments
Revenues	€8m - €9.5m	€8m to €9.5m from licensees (previous guidance €7.5m to €9m) €4m to €4.5m from royalties and sale of remimazolam API (previous guidance: €5m to €6m) €4m to €5m from milestones and upfront payments (previous guidance: €2.5m to €3m) No revenues from own commercialisation of remimazolam, angiotensin II and eravacycline in parts of Europe included in guidance (expected in an amount up to €0.2m) (previous guidance €0.5m)
Cost of revenues	€3m	(previous guidance: €3.5m to €4m)
R&D	€4.5m - €5.5m	Ongoing R&D expenses mainly in connection with market approval applications in the EU
S,G&A	€18m - €20m	Increase due to commercial build-up and launches ca. 10% non-cash (amortisation)
EBIT	€-16.5m - €-20.5m	Previous guidance: €-16.5m to €-21.5m

Source: PAION AG

PAION products answer unmet medical/physician needs and so we remain confident of their long term success Although we have reduced our near term forecasts, we remain confident of the long term success of PAION's products as they answer unmet medical/physician needs. In the anesthesia market, the advantage of remimazolam over midazolam is more rapid onset/offset and over propofol lower cardiovascular/respiratory depression and lower use of resources for supervision during procedures.

Angiotensin II is currently the only drug approved for patients who do not respond either to first line treatment (catecholamines) or second line treatment (vasopressors) for septic shock. The corresponding patient population in the EU is 150,000 annually.

Eravacycline, which is indicated for complex intra-abdominal infections, has a wider spectrum of activity against resistant gram-negative bacteria than any competing antibiotic. This, coupled with a good level of activity against gram-positive and anaerobic microorganisms, suggests to us that the drug is very competitive.

Chinese royalty sale/pending license deals cover half of financing requirement ahead of projected 2023/24 cashflow breakeven PAION signed a financing agreement for a loan of up to €20m with the European Investment Bank in June 2019. The company drew down the first two tranches amounting to €12.5m in February 2021 and the third tranche of €7.5m in June 2021. In April 2021, PAION raised gross proceeds of €7.8m through a rights issue of 5.1m new shares. At the time of the H1/21 report in August, PAION's management estimated the company's outstanding financing requirement ahead of projected cashflow breakeven in 2023/24 in the mid double-digit €m range. The €20.5m proceeds from the sale of the Chinese remimazolam royalties combined with our expectation of an additional €5m in 2022 from further outlicensing deals should provide half this figure and act as a cash runway into 2023. As figure 4 shows, these transactions also reduce our assumed diluted share count by 8.7% to 80.7m (previously: 88.1m). We assume the issue in early 2023 of a €30m convertible bond (convertible at €2) will cover the balance of the financing requirement.

Buy recommendation maintained but price target lowered to €3.80 (previously: €4.10)

We maintain our Buy recommendation but have lowered the price target from €4.10 to €3.80 to reflect lower near-term profitability than forecast in our July 2021 note as well as the removal of the ICU indication from our model.



Figure 3: Valuation model

Compound	Project (1)	Present Value	Patient Pop	Treatment Cost	Market Size	Market Share	Peak Sales	PACME Margin (2)	Discount Factor	Patent Life (3)	Time to Market
Remimazolam	PS US	€114.4M	38,470K	€33	€1,250.3M	14%	€226.7M	20%	12%	11	-
Remimazolam	PS EU + UK	€63.8M	15,144K	€14	€208.6M	20%	€545M	40%	12%	12	-
Remimazolam	PS KOR	€3.7M	2,068K	€17	€34.5M	25%	€11.4M	10%	12%	10	-
Remimazolam	PS CAN	€4.0M	1,056K	€20	€21.1M	50%	€13.4M	18%	15%	8	2 Years
Remimazolam	PS TWN	€7.9M	708K	€30	€21.2M	50%	€13.5M	30%	15%	8	2 Years
Remimazolam	GA JAP	€42.9M	7,100K	€90	€639.0M	10%	€84.3M	16%	12%	13	-
Remimazolam	GA KOR	€3.3M	2,040K	€75	€153.0M	5%	€10.1M	10%	12%	10	-
Remimazolam	GA EU + UK	€94.1M	29,000K	€60	€1,740.0M	5%	€14.8M	40%	15%	10	1 Year
Remimazolam	GA TWN	€3.6M	960K	€60	€48.0M	10%	€6.3M	30%	15%	8	2 Years
Remimazolam	GA US	€41.6M	18,700K	€90	€1,683.0M	10%	€226.1M	20%	15%	6	3 Years
Remimazolam	GA CIS/MENA/TUR	€8.3M	18,416K	€22	€410.2M	10%	€54.1M	12%	15%	7	2 Years
Giapreza	DS EU + UK	€95.5M	90K	€1,413	€127.2M	50%	€70.4M	42%	12%	21	-
Xerava	CIAI EU + UK	€37.6M	690K	€464	€320.0M	10%	€30.6M	36%	12%	19	-
PACME PV		€520.7M									
Costs PV (4)		€271.4M									
NPV		€249.4M									
Milestones PV		€14.0M									
Pro forma net cash		€44.1M									
Fair Value		€307.5M									
Pro forma share count		80,467K									
Price Target		€3.82									

1) A project typically refers to a specific indication or, where necessary or relevant, a combination between indication and geographic market

PS US = Procedural Sedation in the US

PS EU + UK = Procedural Sedation in the EU + UK

PS KOR = Procedural Sedation in Korea

PS CAN = Procedural Sedation in Canada

PS TWN = Procedural Sedation in Taiwan

GA JAP = General Anaesthesia in Japan

GA KOR = General Anaesthesia in South Korea

GA EU + UK = General Anaesthesia in the EU + UK

GA TWN = General Anaesthesia in Taiwan

GA US = General Anaesthesia in the US

GA CIS/MENA/TUR = General Anaesthesia in the Commonwealth of Independent States, Middle East & North Africa, and Turkey

DS EU + UK = Distributive Shock in the EU + UK

CIAI EU + UK = Complicated Intra-abdominal Infections in the EU + UK

2) PACME (Profit After Costs and Marketing Expenses) reflects the company's profit share on future revenues.

This share may be derived in the form of royalties (outsourced marketing/manufacturing) or operating EBITDA margin (in-house model),

3) Remaining patent life in years after the point of approval

4) Includes company-level R&D, G&A, Financing Costs, CapEx and working capital; COGS and S&M are factored into the PACME margin for each project

Source: First Berlin Equity Research estimates

Figure 4: Changes to our pipeline valuation model

	Old	New	Delta
NPV	€322.7M	€249.4M	-22.7%
Milestones PV	€14.9M	€14.0M	-6.0%
Pro Forma Net Cash	€23.3M	€44.1M	89.1%
Fair Value	€360.9M	€307.5M	-14.8%
Diluted Share Count	88.1M	80.5M	-8.7%
Fair Value Per Share	€4.10	€3.82	-6.7%

Source: First Berlin Equity Research estimates



INCOME STATEMENT

All figures in EUR '000	2020	2021E	2022E	2023E	2024E	2025E
Net revenues	100	4,452	10,549	32,201	90,084	212,277
Other op. inc. (including milestones)	19,555	2,600	29,000	5,333	3,150	1,483
Total revenue	19,655	7,052	39,549	37,535	93,234	213,761
Cost of goods sold	0	3,184	6,408	16,869	42,510	94,855
Gross profit	19,655	3,868	33,141	20,666	50,724	118,906
S,G&A	11,869	19,000	26,500	29,495	38,172	55,063
R&D	10,288	5,000	5,000	5,000	5,000	5,000
Other operating income (expense)	-261	-113	0	0	0	0
Operating income (EBIT)	1,583	-20,245	1,641	-13,829	7,552	58,844
Net financial result	-152	-4,643	-2,200	-4,600	-4,600	-3,918
Pre-tax income (EBT)	1,430	-24,888	-559	-18,429	2,952	54,925
Income taxes	792	1,813	500	500	500	500
Net income / loss	2,222	-23,075	-59	-17,929	3,452	55,425
Diluted EPS	0.03	-0.33	0.00	-0.25	0.04	0.58
EBITDA	1,811	-18,310	3,578	-11,889	9,492	60,784
Ratios						
EBIT margin	8.1%	-287.1%	4.2%	-36.8%	8.1%	27.5%
EBITDA margin	9.2%	-259.6%	9.0%	-31.7%	10.2%	28.4%
Net margin	11.3%	-327.2%	-0.1%	-47.8%	3.7%	25.9%
Cash Coverage of Expenses						
Cash / G&A	2.6x	0.5x	0.4x	0.7x	0.3x	0.7x
Cash / R&D	1.9x	1.8x	2.0x	4.1x	2.2x	8.0x
Y-Y Growth						
Total revenue	145.7%	-64.1%	460.8%	-5.1%	148.4%	129.3%
Operating income	n.m.	n.m.	n.m.	n.m.	n.m.	679.2%
Net income/ loss	n.m.	n.m.	n.m.	n.m.	n.m.	1505.5%



BALANCE SHEET

All figures in EUR '000	2020	2021E	2022E	2023E	2024E	2025E
Assets						
Current assets, total	26,278	12,086	15,189	34,585	47,994	125,843
Cash and cash equivalents	19,666	9,062	9,752	20,521	10,846	39,940
Receivables	500	665	1,570	4,805	13,462	31,745
Inventories	1,774	1,109	2,617	8,009	22,436	52,908
Other current assets	4,337	1,250	1,250	1,250	1,250	1,250
Non-current assets, total	2,646	19,869	18,121	16,235	14,349	12,463
Property, plant & equipment	16	20	23	27	31	35
Right-of-use assets	800	920	1,058	1,058	1,058	1,058
Goodwill & other intangibles	1,829	18,929	17,039	15,149	13,259	11,369
Total assets	28,924	31,956	33,310	50,820	62,343	138,306
Shareholders' equity & debt						
Current Liabilities, Total	7,384	3,685	4,305	9,744	24,633	56,079
Convertible bond	0	0	0	0	0	0
Accounts payable	3,907	1,109	2,617	8,009	22,436	52,908
Provisions	2,206	1,500	750	750	750	750
Lease liabilities	551	633	729	729	729	729
Other current liabilities	720	444	209	256	718	1,693
Longterm liabilities, total	250	22,288	22,331	52,331	45,512	34,603
Convertible bond	0	0	0	30,000	30,000	30,000
Long-term debt	0	22,000	22,000	22,000	15,182	4,273
Lease liabilities	250	288	331	331	331	331
Shareholders' equity	21,290	5,983	6,674	-11,255	-7,803	47,623
Total consolidated equity and debt	28,924	31,956	33,310	50,820	62,343	138,306
Ratios						
Current ratio (x)	3.56	3.28	3.53	3.55	1.95	2.24
Quick ratio (x)	3.32	2.98	2.92	2.73	1.04	1.30
Net gearing	-88.6%	231.6%	199.4%	-289.1%	-453.6%	-9.7%
Book value per share (€)	0.32	0.08	0.09	-0.16	-0.11	0.67
Return on equity (ROE)	12.3%	-169.2%	-0.9%	782.9%	-36.2%	278.4%



CASH FLOW STATEMENT

All figures in EUR '000	2020	2021E	2022E	2023E	2024E	2025E
Net result	2,222	-23,075	-59	-17,929	3,452	55,425
Depreciation and amortization	343	1,935	1,937	1,940	1,940	1,940
Changes in working capital	-1,232	513	-1,139	-3,188	-8,195	-17,308
Milestone	0	0	0	0	0	0
Net taxes received	-792	0	0	0	0	0
Other items	365	0	0	0	0	0
Operating cash flow	906	-20,628	739	-19,177	-2,803	40,058
CAPEX	-14	-19,159	-189	-54	-54	-54
Free cash flow	892	-39,786	551	-19,231	-2,857	40,004
Debt financing, net	0	20,000	0	0	-6,818	-10,909
Convertible bond financing, net	0	0	0	30,000	0	0
Lease financing, net	-51	119	139	0	0	0
Equity financing, net	26	7,062	0	0	0	0
Other changes in cash	11	2,000	0	0	0	0
Net cash flows	878	-10,604	690	10,769	-9,675	29,095
Cash, start of the year	18,787	19,666	9,062	9,752	20,521	10,846
Cash, end of the year	19,666	9,062	9,752	20,521	10,846	39,940
Y-Y Growth						
Operating cash flow	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Free cash flow	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
EBITDA/share	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.

Imprint / Disclaimer

First Berlin Equity Research

First Berlin Equity Research GmbH ist ein von der BaFin betreffend die Einhaltung der Pflichten des §85 Abs. 1 S. 1 WpHG, des Art. 20 Abs. 1 Marktmissbrauchsverordnung (MAR) und der Markets Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Durchführungsverordnung und der Markets in Financial Instruments Regulations (MiFIR) beaufsichtigtes Unternehmen.

First Berlin Equity Research GmbH is one of the companies monitored by BaFin with regard to its compliance with the requirements of Section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) Market Abuse Regulation (MAR) and Markets in Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Commission Delegated Regulation and Markets in Financial Instruments Regulations (MiFIR).

Anschrift:

First Berlin Equity Research GmbH
Mohrenstr. 34
10117 Berlin
Germany

Vertreten durch den Geschäftsführer: Martin Bailey

Telefon: +49 (0) 30-80 93 9 680

Fax: +49 (0) 30-80 93 9 687

E-Mail: info@firstberlin.com

Amtsgericht Berlin Charlottenburg HR B 103329 B

UST-Id.: 251601797

Ggf. Inhaltlich Verantwortlicher gem. § 6 MDStV

First Berlin Equity Research GmbH

Authored by: Simon Scholes, Analyst

All publications of the last 12 months were authored by Simon Scholes.

Company responsible for preparation: First Berlin Equity Research GmbH, Mohrenstraße 34, 10117 Berlin

The production of this recommendation was completed on 31 January 2022 at 14:36

Person responsible for forwarding or distributing this financial analysis: Martin Bailey

Copyright© 2022 First Berlin Equity Research GmbH No part of this financial analysis may be copied, photocopied, duplicated or distributed in any form or media whatsoever without prior written permission from First Berlin Equity Research GmbH. First Berlin Equity Research GmbH shall be identified as the source in the case of quotations. Further information is available on request.

INFORMATION PURSUANT TO SECTION 85 (1) SENTENCE 1 OF THE GERMAN SECURITIES TRADING ACT [WPHG], TO ART. 20 (1) OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF APRIL 16, 2014, ON MARKET ABUSE (MARKET ABUSE REGULATION) AND TO ART. 37 OF COMMISSION DELEGATED REGULATION (EU) NO 2017/565 (MIFID) II.

First Berlin Equity Research GmbH (hereinafter referred to as: "First Berlin") prepares financial analyses while taking the relevant regulatory provisions, in particular section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) and art. 37 of Commission Delegated Regulation (EU) no. 2017/565 (MiFID II) into consideration. In the following First Berlin provides investors with information about the statutory provisions that are to be observed in the preparation of financial analyses.

CONFLICTS OF INTEREST

In accordance with art. 37 (1) of Commission Delegated Regulation (EU) no. 2017/565 (MiFID) II and art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) investment firms which produce, or arrange for the production of, investment research that is intended or likely to be subsequently disseminated to clients of the firm or to the public, under their own responsibility or that of a member of their group, shall ensure the implementation of all the measures set forth in accordance with Article 34 (2) lit. (b) of Regulation (EU) 2017/565 in relation to the financial analysts involved in the production of the investment research and other relevant persons whose responsibilities or business interests may conflict with the interests of the persons to whom the investment research is disseminated. In accordance with art. 34 (3) of Regulation (EU) 2017/565 the procedures and measures referred to in paragraph 2 lit. (b) of such article shall be designed to ensure that relevant persons engaged in different business activities involving a conflict of interests carry on those activities at a level of independence appropriate to the size and activities of the investment firm and of the group to which it belongs, and to the risk of damage to the interests of clients.

In addition, First Berlin shall pursuant to Article 5 of the Commission Delegated Regulation (EU) 2016/958 disclose in their recommendations all relationships and circumstances that may reasonably be expected to impair the objectivity of the financial analyses, including interests or conflicts of interest, on their part or on the part of any natural or legal person working for them under a contract, including a contract of employment, or otherwise, who was involved in producing financial analyses, concerning any financial instrument or the issuer to which the recommendation directly or indirectly relates.

With regard to the financial analyses of PAION AG the following relationships and circumstances exist which may reasonably be expected to impair the objectivity of the financial analyses: The author, First Berlin, or a company associated with First Berlin reached an agreement with the PAION AG for preparation of a financial analysis for which remuneration is owed.

Furthermore, First Berlin offers a range of services that go beyond the preparation of financial analyses. Although First Berlin strives to avoid conflicts of interest wherever possible, First Berlin may maintain the following relations with the analysed company, which in particular may constitute a potential conflict of interest:

- The author, First Berlin, or a company associated with First Berlin owns a net long or short position exceeding the threshold of 0,5 % of the total issued share capital of the analysed company;
- The author, First Berlin, or a company associated with First Berlin holds an interest of more than five percent in the share capital of the analysed company;

- The author, First Berlin, or a company associated with First Berlin provided investment banking or consulting services for the analysed company within the past twelve months for which remuneration was or was to be paid;
- The author, First Berlin, or a company associated with First Berlin reached an agreement with the analysed company for preparation of a financial analysis for which remuneration is owed;
- The author, First Berlin, or a company associated with First Berlin has other significant financial interests in the analysed company;

With regard to the financial analyses of PAION AG the following of the aforementioned potential conflicts of interests or the potential conflicts of interest mentioned in Article 6 paragraph 1 of the Commission Delegated Regulation (EU) 2016/958 exist: The author, First Berlin, or a company associated with First Berlin reached an agreement with the PAION AG for preparation of a financial analysis for which remuneration is owed.

In order to avoid and, if necessary, manage possible conflicts of interest both the author of the financial analysis and First Berlin shall be obliged to neither hold nor in any way trade the securities of the company analyzed. The remuneration of the author of the financial analysis stands in no direct or indirect connection with the recommendations or opinions represented in the financial analysis. Furthermore, the remuneration of the author of the financial analysis is neither coupled directly to financial transactions nor to stock exchange trading volume or asset management fees.

INFORMATION PURSUANT TO SECTION 64 OF THE GERMAN SECURITIES TRADING ACT [WPHG], DIRECTIVE 2014/65/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 15 MAY 2014 ON MARKETS IN FINANCIAL INSTRUMENTS AND AMENDING DIRECTIVE 2002/92/EC AND DIRECTIVE 2011/61/EU, ACCOMPANIED BY THE MARKETS IN FINANCIAL INSTRUMENTS REGULATION (MIFIR, REG. EU NO. 600/2014).

First Berlin notes that it has concluded a contract with the issuer to prepare financial analyses and is paid for that by the issuer. First Berlin makes the financial analysis simultaneously available for all interested security financial services companies. First Berlin thus believes that it fulfils the requirements of section 64 WpHG for minor non-monetary benefits.

PRICE TARGET DATES

Unless otherwise indicated, current prices refer to the closing prices of the previous trading day.

AGREEMENT WITH THE ANALYSED COMPANY AND MAINTENANCE OF OBJECTIVITY

The present financial analysis is based on the author's own knowledge and research. The author prepared this study without any direct or indirect influence exerted on the part of the analysed company. Parts of the financial analysis were possibly provided to the analysed company prior to publication in order to avoid inaccuracies in the representation of facts. However, no substantial changes were made at the request of the analysed company following any such provision.

ASSET VALUATION SYSTEM

First Berlin's system for asset valuation is divided into an asset recommendation and a risk assessment.

ASSET RECOMMENDATION

The recommendations determined in accordance with the share price trend anticipated by First Berlin in the respectively indicated investment period are as follows:

Category		1	2
Current market capitalisation (in €)		0 - 2 billion	> 2 billion
Strong Buy ¹	An expected favourable price trend of:	> 50%	> 30%
Buy	An expected favourable price trend of:	> 25%	> 15%
Add	An expected favourable price trend of:	0% to 25%	0% to 15%
Reduce	An expected negative price trend of:	0% to -15%	0% to -10%
Sell	An expected negative price trend of:	< -15%	< -10%

¹ The expected price trend is in combination with sizable confidence in the quality and forecast security of management.

Our recommendation system places each company into one of two market capitalisation categories. Category 1 companies have a market capitalisation of €0 – €2 billion, and Category 2 companies have a market capitalisation of > €2 billion. The expected return thresholds underlying our recommendation system are lower for Category 2 companies than for Category 1 companies. This reflects the generally lower level of risk associated with higher market capitalisation companies.

RISK ASSESSMENT

The First Berlin categories for risk assessment are low, average, high and speculative. They are determined by ten factors: Corporate governance, quality of earnings, management strength, balance sheet and financial risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, strength of brandname, market capitalisation and free float. These risk factors are incorporated into the First Berlin valuation models and are thus included in the target prices. First Berlin customers may request the models.

RECOMMENDATION & PRICE TARGET HISTORY

Report No.:	Date of publication	Previous day closing price	Recommendation	Price target
Initial Report	2 April 2012	€0.79	Buy	€2.00
2...40	↓	↓	↓	↓
41	21 August 2019	€2.26	Buy	€4.20
42	19 February 2020	€2.22	Buy	€3.80
43	23 April 2020	€1.74	Buy	€3.60
44	9 July 2020	€2.93	Buy	€4.90
45	17 August 2020	€2.69	Buy	€4.90
46	9 December 2020	€2.45	Buy	€4.90
47	12 July 2021	€1.91	Buy	€4.10
49	Today	€1.39	Buy	€3.80

INVESTMENT HORIZON

Unless otherwise stated in the financial analysis, the ratings refer to an investment period of twelve months.

UPDATES

At the time of publication of this financial analysis it is not certain whether, when and on what occasion an update will be provided. In general First Berlin strives to review the financial analysis for its topicality and, if required, to update it in a very timely manner in connection with the reporting obligations of the analysed company or on the occasion of ad hoc notifications.

SUBJECT TO CHANGE

The opinions contained in the financial analysis reflect the assessment of the author on the day of publication of the financial analysis. The author of the financial analysis reserves the right to change such opinion without prior notification.

Legally required information regarding

- key sources of information in the preparation of this research report
- valuation methods and principles
- sensitivity of valuation parameters

can be accessed through the following internet link: <https://firstberlin.com/disclaimer-english-link/>

SUPERVISORY AUTHORITY: Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) [BaFin], Graurheindorferstraße 108, 53117 Bonn and Marie-Curie-Straße 24-28, 60439 Frankfurt am Main

EXCLUSION OF LIABILITY (DISCLAIMER)

RELIABILITY OF INFORMATION AND SOURCES OF INFORMATION

The information contained in this study is based on sources considered by the author to be reliable. Comprehensive verification of the accuracy and completeness of information and the reliability of sources of information has neither been carried out by the author nor by First Berlin. As a result no warranty of any kind whatsoever shall be assumed for the accuracy and completeness of information and the reliability of sources of information, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the accuracy and completeness of information and the reliability of sources of information.

RELIABILITY OF ESTIMATES AND FORECASTS

The author of the financial analysis made estimates and forecasts to the best of the author's knowledge. These estimates and forecasts reflect the author's personal opinion and judgement. The premises for estimates and forecasts as well as the author's perspective on such premises are subject to constant change. Expectations with regard to the future performance of a financial instrument are the result of a measurement at a single point in time and may change at any time. The result of a financial analysis always describes only one possible future development – the one that is most probable from the perspective of the author – of a number of possible future developments.

Any and all market values or target prices indicated for the company analysed in this financial analysis may not be achieved due to various risk factors, including but not limited to market volatility, sector volatility, the actions of the analysed company, economic climate, failure to achieve earnings and/or sales forecasts, unavailability of complete and precise information and/or a subsequently occurring event which affects the underlying assumptions of the author and/or other sources on which the author relies in this document. Past performance is not an indicator of future results; past values cannot be carried over into the future.

Consequently, no warranty of any kind whatsoever shall be assumed for the accuracy of estimates and forecasts, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the correctness of estimates and forecasts.

INFORMATION PURPOSES, NO RECOMMENDATION, SOLICITATION, NO OFFER FOR THE PURCHASE OF SECURITIES

The present financial analysis serves information purposes. It is intended to support institutional investors in making their own investment decisions; however in no way provide the investor with investment advice. Neither the author, nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be considered to be acting as an investment advisor or portfolio manager vis-à-vis an investor. Each investor must form his own independent opinion with regard to the suitability of an investment in view of his own investment objectives, experience, tax situation, financial position and other circumstances.

The financial analysis does not represent a recommendation or solicitation and is not an offer for the purchase of the security specified in this financial analysis. Consequently, neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall as a result be liable for losses incurred through direct or indirect employment or use of any kind whatsoever of information or statements arising out of this financial analysis.

A decision concerning an investment in securities should take place on the basis of independent investment analyses and procedures as well as other studies including, but not limited to, information memoranda, sales or issuing prospectuses and not on the basis of this document.

NO ESTABLISHMENT OF CONTRACTUAL OBLIGATIONS

By taking note of this financial analysis the recipient neither becomes a customer of First Berlin, nor does First Berlin incur any contractual, quasi-contractual or pre-contractual obligations and/or responsibilities toward the recipient. In particular no information contract shall be established between First Berlin and the recipient of this information.

NO OBLIGATION TO UPDATE

First Berlin, the author and/or the person responsible for passing on or distributing the financial analysis shall not be obliged to update the financial analysis. Investors must keep themselves informed about the current course of business and any changes in the current course of business of the analysed company.

DUPLICATION

Dispatch or duplication of this document is not permitted without the prior written consent of First Berlin.

SEVERABILITY

Should any provision of this disclaimer prove to be illegal, invalid or unenforceable under the respectively applicable law, then such provision shall be treated as if it were not an integral component of this disclaimer; in no way shall it affect the legality, validity or enforceability of the remaining provisions.

APPLICABLE LAW, PLACE OF JURISDICTION

The preparation of this financial analysis shall be subject to the law obtaining in the Federal Republic of Germany. The place of jurisdiction for any disputes shall be Berlin (Germany).

NOTICE OF DISCLAIMER

By taking note of this financial analysis the recipient confirms the binding nature of the above explanations.

By using this document or relying on it in any manner whatsoever the recipient accepts the above restrictions as binding for the recipient.

QUALIFIED INSTITUTIONAL INVESTORS

First Berlin financial analyses are intended exclusively for qualified institutional investors.

This report is not intended for distribution in the USA and/or Canada.